ALYMSYS vs GAVRETO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 8, 2026·How we rate

Possible drug interaction. ALYMSYS and GAVRETO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	ALYMSYS	GAVRETO
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-MALY	PRALSETINIB
Manufacturer	Amneal	Rigel Pharms
Dosage forms	Injectable	Capsule
Drug class	—	—
Boxed warning	None	Boxed warning
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Non-Small-Cell Lung Carcinoma

alymsys gavreto

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-MALY

PRALSETINIB

Manufacturer

Amneal

Rigel Pharms

Dosage forms

Injectable

Capsule

Drug class

—

Boxed warning

None

Boxed warning

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Alymsys and Gavreto?

Alymsys contains Bevacizumab-Maly, while Gavreto contains Pralsetinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.